Determined the stage of endometrial cancer for its surgical treatment

TO THE EDITORS: Marchocki et al 1 addressed an important topic regarding sentinel lymph node (SLN) mapping for high-grade endometrial cancer (EC) cases to determine the value of pelvic lymphadenectomy with hysterectomy in its treatment. Although the article stated that SLN biopsy was considered as the “standard of care” for the participating centers included in the study, other methodologies for determining the staging of EC using different imaging techniques should be strongly considered as a best practice. This is especially true, given the well-recognized confusion and difficulties using such SLN mapping, with its use of different dyes (colorimetric and radioactive) and dye injection sites and the possible need for surgeon certification for its performance, as is stated in the article. The 100% accuracy of using preoperative 3-dimensional transvaginal sonography for this has been documented multiple times from different authors,2–4 and this should not be ignored. The use of SLN mapping to optimally select those cases of EC benefiting from pelvic lymphadenectomy in high-stage or low-stage EC cases is certainly worthwhile. However, comparing the practical case, associated cost, and overall generalizability of these diagnostic techniques5 must be considered before any “standard of care” is recognized. Moreover, the reproducibility and consistency of performing SLN mapping, the availability and accuracy of the frozen section,6 and the preoperative prediction of the staging of EC are important to consider. Evidence obtained from meta-analyses along with practicality should dictate standard medical practice, in terms of the optimal method to use in preparation for the surgical treatment of EC, whether to expect to perform a pelvic lymphadenectomy. The benefit of lymphadenectomy performance for stage IB has been suggested, with its greater risk of lymph node metastasis, if it is known at the time of surgery.7

Elliot M. Levine, MD
Department of Obstetrics and Gynecology
 Advocate Illinois Masonic Medical Center
836 W. Wellington

Carlos M. Fernandez, MD
Director of Gynecologic Ultrasound
Department of Obstetrics and Gynecology
 Advocate Illinois Masonic Medical Center
Chicago, IL

The authors report no conflict of interest.

This study received no funding.

REFERENCES

© 2022 Elsevier Inc. All rights reserved. https://doi.org/10.1016/j.ajog.2022.02.014

Sentinel lymph node biopsy in high-grade endometrial cancer

We thank Levine and Fernandez for their interest in our study,1 and we agree that the implementation of sentinel lymph node (SLN) biopsy into clinical practice may be associated with an additional certification requirement and learning curve. However, we do not view this process as a barrier but rather as a form of quality assurance required for all new surgical techniques to ensure patient safety.

Endometrial cancer (EC) is staged surgically to determine the most appropriate adjuvant treatment, as lymph node status is one of the most important prognostic factors for survival.2 Traditionally, full pelvic and para-aortic lymphadenectomies have been recommended as part of the staging for patients with high-grade EC. However, randomized controlled trials have demonstrated that lymphadenectomy